The prosthesis may be designed to be turned on manually when the patient senses the imminence of a convulsion.
Alternatively, sensors (48, 50) may be provided for determining changes in the values of state parameters such as electroencephalographic waves which precede a convulsion.
The present invention relates to the detection of seizure disorders such as epilepsy.
Other embodiments include prediction of seizure activity based upon analysis of physiological signal levels.
A further embodiment of the invention includes detection of seizure activity following the delivery of therapy.
A diluted solution of ceftiofur sodium is intrathecally or ventricularly delivered to effectively treat bacterial meningitis while maintaining the patient's threshold and reducing the likelihood of seizure.
The present invention relates to the anticonvulsant activity of GSK-3βinhibitors and the use of GSK-3β inhibitors as agents for the treatment of neurological disorders characterized by seizures such as epilepsy.
Anticonvulsant derivatives of formula (I) useful in treating cocaine dependency are disclosed.
Such acetone derivatives show higher anticonvulsant activity and improved therapeutic indexes over acetone itself.
The current invention combines the use of an opioid antagonist with at least one anticonvulsant for the treatment of alcoholism.
Anticonvulsant derivatives of formula (I) useful for preventing the development of Type II diabetes mellitus and Syndrome X are disclosed.
Treatment of psychotic disorders such as schizophrenia, schizophreniform and schizoaffective disorders comprising co-therapy with an anticonvulsant derivative and atypical antipsychotic.
To increase an image, the DCT coefficients of the original image are operated on to produce coefficients of the larger image, then the convolution-multiplication property of the DCT is used to implement an anti-imaging filter.
The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, antipsychotics, antiemetics, or in improving the cognitive function of the brain of mammals.
Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an antidiabetic and the second compound is a anticonvulsant.